Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt repayments (2017 - 2025)

Myriad Genetics has reported Short-Term Debt repayments over the past 7 years, most recently at $60.0 million for Q3 2025.

  • Quarterly Short-Term Debt repayments rose 200.0% to $60.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $80.5 million through Dec 2025, down 32.64% year-over-year, with the annual reading at $80.5 million for FY2025, 32.64% down from the prior year.
  • Short-Term Debt repayments was $60.0 million for Q3 2025 at Myriad Genetics, up from $20.5 million in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at $106.4 million in Q3 2021 and troughed at $19.5 million in Q4 2024.
  • The 4-year median for Short-Term Debt repayments is $45.0 million (2021), against an average of $46.6 million.
  • The largest YoY upside for Short-Term Debt repayments was 200.0% in 2025 against a maximum downside of 65.83% in 2025.
  • A 4-year view of Short-Term Debt repayments shows it stood at $106.4 million in 2021, then tumbled by 62.41% to $40.0 million in 2023, then crashed by 51.25% to $19.5 million in 2024, then soared by 207.69% to $60.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Short-Term Debt repayments are $60.0 million (Q3 2025), $20.5 million (Q1 2025), and $19.5 million (Q4 2024).